Clinical Context and Decision-Making Surrounding Early Discontinuation of Adjuvant Immune Checkpoint Inhibitors in Genitourinary Malignancies: A Real-World Cohort Study

Abstract Purpose Adjuvant immune checkpoint inhibitors (ICIs) are increasingly used for genitourinary malignancies after curative-intent surgery; however, real-world treatment persistence and the circumstances surrounding early discontinuation are unclear. We evaluated treatment completion and the clinical circumstances and decision-making surrounding permanent discontinuation. Methods We retrospectively evaluated 39 consecutive patients who were administered adjuvant pembrolizumab for renal cell carcinoma or nivolumab for urothelial carcinoma at a single center from 2022 to 2025; the data cut-off date was October 8, 2026. The primary outcome was the completion of a planned 1-year treatment among patients with a definitive completion status. The two cohorts were analyzed descriptively without direct comparison. Results Of 37 patients with a definitive treatment status, 20 completed planned therapy (54.1%; 95% confidence interval, 36.9–70.5%) and 17 permanently discontinued treatment before completion (45.9%). The remaining two patients (5.1% of 39) were still on treatment at data cut-off. An adverse event was the documented primary reason for discontinuation in 12 of 17 patients (70.6%); 11 of these 12 (91.7%) followed Grade 1–2 events. Patient preference contributed to nine of 17 discontinuations (52.9%) through patient-initiated or shared decision-making. Grade ≥ 3 adverse events occurred in two patients (5.1%). Conclusions In this retrospective cohort, permanent discontinuation of adjuvant ICI therapy was frequently documented in association with low-grade toxicity and with patient preference, whereas Grade ≥ 3 toxicity was uncommon. Shared decision-making that balances anticipated recurrence-risk reduction against treatment burden represents an important consideration in individualizing adjuvant immunotherapy.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11575221/v1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Clinical Context and Decision-Making Surrounding Early Discontinuation of Adjuvant Immune Checkpoint Inhibitors in Genitourinary Malignancies: A Real-World Cohort Study

Atsushi Yanase, Masayuki Kurokawa, Toru Sugihara, Eiichiro Takaoka et al.
2 links
Research Square
Cancer Immunotherapy and Biomarkers
preprint

Clinical Context and Decision-Making Surrounding Early Discontinuation of Adjuvant Immune Checkpoint Inhibitors in Genitourinary Malignancies: A Real-World Cohort Study

Atsushi Yanase, Masayuki Kurokawa, Toru Sugihara, Eiichiro Takaoka, Hayato Hoshina, Tetsuya Fujimura, Haruki Kume
preprint en

Abstract

Abstract Purpose Adjuvant immune checkpoint inhibitors (ICIs) are increasingly used for genitourinary malignancies after curative-intent surgery; however, real-world treatment persistence and the circumstances surrounding early discontinuation are unclear. We evaluated treatment completion and the clinical circumstances and decision-making surrounding permanent discontinuation. Methods We retrospectively evaluated 39 consecutive patients who were administered adjuvant pembrolizumab for renal cell carcinoma or nivolumab for urothelial carcinoma at a single center from 2022 to 2025; the data cut-off date was October 8, 2026. The primary outcome was the completion of a planned 1-year treatment among patients with a definitive completion status. The two cohorts were analyzed descriptively without direct comparison. Results Of 37 patients with a definitive treatment status, 20 completed planned therapy (54.1%; 95% confidence interval, 36.9–70.5%) and 17 permanently discontinued treatment before completion (45.9%). The remaining two patients (5.1% of 39) were still on treatment at data cut-off. An adverse event was the documented primary reason for discontinuation in 12 of 17 patients (70.6%); 11 of these 12 (91.7%) followed Grade 1–2 events. Patient preference contributed to nine of 17 discontinuations (52.9%) through patient-initiated or shared decision-making. Grade ≥ 3 adverse events occurred in two patients (5.1%). Conclusions In this retrospective cohort, permanent discontinuation of adjuvant ICI therapy was frequently documented in association with low-grade toxicity and with patient preference, whereas Grade ≥ 3 toxicity was uncommon. Shared decision-making that balances anticipated recurrence-risk reduction against treatment burden represents an important consideration in individualizing adjuvant immunotherapy.

Research Square
Jichi Medical University Hospital (JP), The University of Tokyo (JP)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon